KALVISTA PHARMACEUTICALS, INC. (NASDAQ:KALV) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

On May 30, 2017, KalVista Pharmaceuticals, Inc. (the “Company” or “KalVista”) entered into an Office Lease Agreement (the “Lease”) with 55 Cambridge Parkway, LLC (the “Landlord”), to which the Company will lease approximately 2,762 square feet of space located on the 9th Floor at 55 Cambridge Parkway, Cambridge, MA (the “Premises”).

The Lease provides for a term of five years (the “Term”), commencing on the earlier of (i) the date on which the Landlord substantially completes the Tenant Improvements (as defined in the Lease), or (ii) the Company’s occupancy of the Premises for business purposes.

to the Lease, annual base rent will be $80.00/sq. ft. for the first year from the commencement of the Term and is subject to annual increases of $1.00/sq. ft. as well as other adjustments under certain circumstances.

The foregoing description of the Lease is a summary, is not complete, and is qualified in its entirety by the terms and conditions of the actual lease, which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended April 30, 2017.

About KALVISTA PHARMACEUTICALS, INC. (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.

KALVISTA PHARMACEUTICALS, INC. (NASDAQ:KALV) Recent Trading Information

KALVISTA PHARMACEUTICALS, INC. (NASDAQ:KALV) closed its last trading session up +0.19 at 7.12 with 7,827 shares trading hands.